Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 17 ... Current study results from the report, 'Clinical phenotype of cystic fibrosis patients with the G551D mutation,' have been published. "Data on whether the phenotype ...
2009 NOV 23 ... in innate immunity, where they dominate the response to infections, in particular in the cystic fibrosis lung. PMNs are phagocytic cells that produce a wide range of antimicrobial agents aimed ...
2009 NOV 23 ... children under the age of 18 in the U.S., killing more children than asthma, diabetes, cystic fibrosis and AIDS combined(2). Yet, approximately half of the oncology drugs used to treat ...
2009 NOV 23 ... the molecular and cellular processes responsible for the development of lung disease in cystic fibrosis (CF) has led to evaluation of a broad range of new therapies within multiple therapeutic ...
2009 NOV 23 ... of Bacteriology, "Pseudomonas aeruginosa colonizes and can persist in the lungs of cystic fibrosis (CF) patients for decades. Adaptation of P. aeruginosa to the CF lung environment causes ...
2009 NOV 24 ... recommendations and barriers to their implementation as experienced by multidisciplinary cystic fibrosis (CF) care providers. In addition, controversies regarding optimal infection control will ...
2009 NOV 23 ... and phospholipase C beta 2 (PLC beta 2) as taste-signaling molecules, and cystic fibrosis transmembrane regulator (CFTR) and Clara-cell-specific secretory protein of 10-kDa ...
2009 NOV 28 ... was assessed using the EQ-5D-Y (new EQ-5D version for children and adolescents) and the Cystic Fibrosis Questionnaire (CFQ). The objective of the study is to evaluate the cross-sectional ...
2009 NOV 24 ... in immunocompromised individuals, including individuals with the heritable disease cystic fibrosis. Like the carbon sources metabolized by many disease-causing bacteria, the carbon ...
2009 NOV 24 ... France conducted a study "To determine the frequency and types of mutations causing cystic fibrosis (CF) in Tunisia. We analyzed the complete coding region and flanking intronic sequences ...
2009 NOV 27 ... aeruginosa is implicated in nosocomial infections and chronic respiratory infections in cystic fibrosis patients. Chlorhexidine diacetate(CHX) is a biguanide disinfectant used for bacterial ...
2009 NOV 23 ... This review will examine what is now known about palliative and end-of-life care for cystic fibrosis (CF) patients, including the changing demographics and context of such care, and then ...
2009 NOV 23 ... Commercial Launch and Future Launch Plans - The company launched the SensiGene™ Cystic Fibrosis (CF) Carrier Screening Test, its first LDT, through its CLIA laboratory in September. ...
2009 NOV 16 ... Pseudomonas aeruginosa is the leading cause of morbidity and mortality in patients with cystic fibrosis. The pulmonary delivery of antimicrobial agents provides high concentrations of drug ...
2009 NOV 16 ... efficacy in chronic Pseudomonus aeruginosa (PA) infection in patients with cystic fibrosis (CF) in comparison to the usual application of 200 mg/kg per day ceftazidime in three ...
2009 NOV 23 ... in the U.S. and 12.5 million worldwide. In fact, in the U.S., more people have PKD than cystic fibrosis, sickle cell anemia, hemophilia, muscular dystrophy, Down's syndrome and Huntington's ...
